| Objective: To observe the affection of Baogan Xiaozhi granule on non-alcoholic fatty liver Patients, (liver stagnation and spleen deficiency type) serum leptin levels,Preliminarily study one Part of the possible mechanism of Baogan Xiaozhi granule.Methods:The protocol for this study including 60 patients with NAFLD was employed, which was accorded to the income standard. The patients were randomly divided into treatment group (30 cases) and control group (30 cases). The patients took Baoganxiaozhi granule in treatment group, and xinfatating tablet in control group. The period of treatment was 30 days.in each group. The situation of patients were observed and compared, including the clinical syndrome and sign, the degree of seriousness with ultrasound checking, and the change of serum ALT,AST,TG, CHOL,leptin。Results:①treatment group and control group TCM total effective rates were 96.55%,88.88%,the difference between groups was statistically significant(P<0.05).But also in the process of clinical observation, we found that Baogan Xiaozhi granule can significantly improve the non-alcoholic fatty liver pain in patients with flank pain, bloating, diarrhea, bad mood, symptoms of abdominal pain and want to vent, and no obvious side effects;②ultrasound After treatment, liver total efficiency test results were: 34.49%,33.33%,no significant difference between the two groups(P>0.05);③treatment group compared with the control group before the treatment can significantly reduce the serum ALT,AST,TG, CHOL, serum leptin(P<0.05),but the treatment group and control group ALT, AST, CHOL, leptin group showed no significant difference(P>0.05), TG group difference significant, statistically significant.Conclusion:1.Baogan Xiaozhi granule can reduce the non-alcoholic fatty liver in patients with symptoms and signs, improve liver function;2.BaoganXiaozhigranule can decrease serum ALT,AST,TG,CHOL Levels and can improve the degree of fatty liver under ultrasound;3.Baogan Xiaozhi granule can significantly decrease serum leptin levels in patients with non-alcoholic fatty liver. |